HSBC lifts Regeneron price target to $920
Analysts expect a potential two-year U.S. patent extension for Dupixent and HSBC raised its REGN price target to $920 with a Buy rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.